March 27 (Reuters) - Amoeba SA AMEBA.PA :
* FY OPERATING LOSS EUR 5.5 MILLION VERSUS LOSS OF EUR 6.1 MILLION YEAR AGO
* AMOEBA: 2019 ANNUAL RESULTS IN LINE WITH DEVELOPMENT PLAN
* FY NET LOSS EUR 7.3 MILLION VERSUS LOSS OF EUR 7.2 MILLION YEAR AGO
* FY REVENUE EUR 0.1 MILLION VERSUS EUR 0.1 MILLION YEAR AGO
* AT 31 DEC 2019, THE COMPANY'S EQUITY AMOUNTS TO 4.2 M€ COMPARED TO 5.4 M€
AT 31
DEC 2018
* CASH AND CASH EQUIVALENTS AMOUNT TO € 4.8 MILLION COMPARED TO € 3.5
MILLION AT
DECEMBER 31, 2018.
* END-DEC CASH AND CASH EQUIVALENTS AMOUNT TO € 4.8 MILLION VERSUS € 3.5
MILLION
AT DEC 31, 2018
* ON COVID-19: COMPANY REMAINS ORGANIZED TO ENSURE CONTINUITY OF ACTIVITIES,
NAMELY RESEARCH, FIELD TRIALS AND FINALIZATION OF REGULATORY FILES
* THE EUROPEAN DOSSIER, WHOSE SUBMISSION WAS SCHEDULED FOR END OF MARCH,
WILL BE
SUBMITTED TO AUSTRIAN COMPETENT AUTHORITY BEFORE END OF MAY
* COMPANY HAS CARRIED OUT AN ANALYSIS OF ITS CASH FLOW FORECAST, WHICH
ENABLES IT
TO FINANCE ITS NEEDS WITHOUT ADDITIONAL REVENUES UNTIL AUGUST 2021
Further company coverage: AMEBA.PA
(Gdansk Newsroom)
((Gdansk.newsroom@thomsonreuters.com; +48 58 778 51 10;))